<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03504800</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#000018036</org_study_id>
    <nct_id>NCT03504800</nct_id>
  </id_info>
  <brief_title>OCT in Diagnosis of Irregular Corneas</brief_title>
  <official_title>Optical Coherence Tomography-Aided Differential Diagnosis and Treatment of Irregular Corneas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This main goal of this study is to improve the detection, classification, monitoring, and&#xD;
      treatment of irregular corneas due to keratoconus, warpage, dry eye, scar, stromal&#xD;
      dystrophies, and other corneal conditions.&#xD;
&#xD;
      The primary goal will be achieved by using optical coherence tomography (OCT) to:&#xD;
&#xD;
        1. Develop an OCT-based system to classify and evaluate corneal-shape irregularities.&#xD;
&#xD;
        2. Develop OCT metrics for more sensitive detection of keratoconus progression.&#xD;
&#xD;
        3. Develop OCT-and-topography guided phototherapeutic keratectomy (PTK) for irregular&#xD;
           corneas.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Develop OCT-based system to classify and evaluate corneal-shape irregularities</measure>
    <time_frame>1 day</time_frame>
    <description>Clinical classification of keratoconus, epithelial deformation, stromal addition/subtraction, stromal distortion, and healthy controls by OCT. Primary measurements will be corneal and epithelial thicknesses assessed in micron units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Develop OCT-based system to classify and evaluate corneal-shape irregularities</measure>
    <time_frame>1 day</time_frame>
    <description>Secondary measurement will be OCT corneal shape assessed in Diopter units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Develop OCT metrics for more sensitive detection of keratoconus progression</measure>
    <time_frame>4 year</time_frame>
    <description>Primary measurements will be OCT corneal and epithelial thicknesses assessed in micron units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Develop OCT metrics for more sensitive detection of keratoconus progression</measure>
    <time_frame>4 year</time_frame>
    <description>Secondary measurement will be OCT corneal shape assessed in Diopter units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Develop OCT- and topography-guided phototherapeutic keratectomy (PTK) for irregular corneas</measure>
    <time_frame>1 year</time_frame>
    <description>The primary goal is to improve the post-procedural outcome of uncorrected and best corrected visual acuity. This will be measured in feet by conventional Snellen fraction of 20/xx.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Develop OCT- and topography-guided phototherapeutic keratectomy (PTK) for irregular corneas</measure>
    <time_frame>1 year</time_frame>
    <description>The secondary goal is to improve the post-procedural outcome of refractive error. This will be measured in Diopter units.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">445</enrollment>
  <condition>Keratoconus</condition>
  <condition>Corneal Opacity</condition>
  <condition>Corneal Dystrophy</condition>
  <arm_group>
    <arm_group_label>Group A: Classification of Corneal Irregularities</arm_group_label>
    <description>This group will consist of participants &gt;14 years old with various types of corneal irregularities. Their data will be compared against participants with healthy corneas. Data for this group will be gathered only once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Detection of Keratoconus Progression</arm_group_label>
    <description>Participants from Group A who are diagnosed with keratoconus will be selected for this longitudinal study to monitor keratoconus progression. They will be followed up to 4 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: OCT-and-Topography Guided PTK</arm_group_label>
    <description>Participants from Group A will be selected for this group if they have vision primarily limited by scars, dystrophy, or high astigmatism that could be treated by PTK. They will be followed up to 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical Coherence Tomography</intervention_name>
    <description>This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B &amp; C.</description>
    <arm_group_label>Group A: Classification of Corneal Irregularities</arm_group_label>
    <arm_group_label>Group B: Detection of Keratoconus Progression</arm_group_label>
    <arm_group_label>Group C: OCT-and-Topography Guided PTK</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 445 participants ages 14 or older will be recruited for the 3 clinical studies.&#xD;
        All 3 studies will be performed at the Casey Eye Institute at Oregon Health &amp; Science&#xD;
        University.&#xD;
&#xD;
        Group A:&#xD;
&#xD;
          -  Keratoconus: 150 participants&#xD;
&#xD;
          -  Epithelial deformation: 105 participants; This category includes contact lens-related&#xD;
             corneal warpage, dry eye, and EBMD.&#xD;
&#xD;
          -  Primary stromal changes: 100 participants; This category includes corneal scars,&#xD;
             Salzmann's degeneration, stromal dystrophies, complicated LASIK/PRK cases with visual&#xD;
             complaints, RK cases, and corneal transplants.&#xD;
&#xD;
          -  Healthy Controls: 90 participants&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        GROUP A:&#xD;
&#xD;
          -  Keratoconus:&#xD;
&#xD;
               1. CDVA ≥ 20/25 in the better eye; and both of the following in the worse eye&#xD;
&#xD;
               2. Topography characteristic of keratoconus or pellucid marginal degeneration&#xD;
&#xD;
          -  Contact lens-related corneal warpage:&#xD;
&#xD;
               1. Contact lens use; and&#xD;
&#xD;
               2. Topography irregularities&#xD;
&#xD;
          -  Dry eye:&#xD;
&#xD;
               1. Symptoms of dry eye documented by Ocular Surface Disease Index (OSDI)&#xD;
                  questionnaire score ≥ 30; and&#xD;
&#xD;
               2. Topography irregularities&#xD;
&#xD;
               3. Presence of punctate epithelial erosion on exam with surface staining&#xD;
&#xD;
               4. Aqueous deficiency or evaporative dry eye&#xD;
&#xD;
          -  Epithelial basement membrane dystrophy (EBMD):&#xD;
&#xD;
               1. Negative corneal fluorescein staining; and&#xD;
&#xD;
               2. Corneal opacities; and&#xD;
&#xD;
               3. Topography irregularities&#xD;
&#xD;
          -  Stromal addition or subtraction:&#xD;
&#xD;
               1. Scars; or&#xD;
&#xD;
               2. Salzmann's degeneration; or&#xD;
&#xD;
               3. Stromal dystrophies; or&#xD;
&#xD;
               4. Complication (visual complaints) after LASIK or photorefractive keratectomy (PRK)&#xD;
&#xD;
          -  Stromal distortion:&#xD;
&#xD;
               1. Radial keratectomy (RK); or&#xD;
&#xD;
               2. Corneal transplants.&#xD;
&#xD;
          -  Normal controls:&#xD;
&#xD;
               1. Healthy eyes with no previous eye procedures/surgeries.&#xD;
&#xD;
        GROUP B:&#xD;
&#xD;
        Participants will be selected from the keratoconus population in Group A based on&#xD;
        topography findings.&#xD;
&#xD;
        GROUP C:&#xD;
&#xD;
        Participants will be selected from the stromal addition/subtraction and stromal distortion&#xD;
        populations of Group A if they have vision primarily limited by scars, dystrophy, or high&#xD;
        astigmatism that could benefit from PTK.&#xD;
&#xD;
        Exclusion Criteria (all groups):&#xD;
&#xD;
          -  Inability to give informed consent.&#xD;
&#xD;
          -  Inability to maintain fixation for OCT imaging.&#xD;
&#xD;
          -  Inability to commit to required study visits.&#xD;
&#xD;
          -  Eyes with concurrent cataract, retinal disease, glaucoma, or other eye conditions that&#xD;
             may limit the visual outcome after surgery.&#xD;
&#xD;
          -  Previous corneal surgeries if considered as a keratoconus participant.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Humberto Martinez, COT</last_name>
    <phone>503-494-7712</phone>
    <email>martinhu@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Denny Romfh, OD</last_name>
    <phone>503-494-4351</phone>
    <email>romfhd@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Humberto Martinez</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Humberto Martinez, COT</last_name>
      <phone>503-494-7712</phone>
      <email>martinhu@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Denny Romfh, OD</last_name>
      <phone>503-494-4351</phone>
      <email>romfhd@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Huang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Winston Chamberlain, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Stutzman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Afshan Nanji, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ellen Davis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seema Gupta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>David Huang</investigator_full_name>
    <investigator_title>Yan Li, PhD, Assistant Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>OCT</keyword>
  <keyword>Keratoconus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Corneal Dystrophies, Hereditary</mesh_term>
    <mesh_term>Corneal Opacity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

